Extraordinary and prolonged erlotinib-induced clinical response in a patient with EGFR wild-type squamous lung cancer in third-line therapy: a case report

Several small molecules, epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib and afatinib, have been demonstrated to significantly improve clinical outcomes in patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC), but erlotinib ac...

Descripción completa

Detalles Bibliográficos
Autores principales: Gambale, Elisabetta, Carella, Consiglia, Amerio, Paolo, Buttitta, Fiamma, Patea, Rosa Lucia, Natoli, Clara, De Tursi, Michele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5449169/
https://www.ncbi.nlm.nih.gov/pubmed/28579838
http://dx.doi.org/10.2147/IMCRJ.S134944
_version_ 1783239731067224064
author Gambale, Elisabetta
Carella, Consiglia
Amerio, Paolo
Buttitta, Fiamma
Patea, Rosa Lucia
Natoli, Clara
De Tursi, Michele
author_facet Gambale, Elisabetta
Carella, Consiglia
Amerio, Paolo
Buttitta, Fiamma
Patea, Rosa Lucia
Natoli, Clara
De Tursi, Michele
author_sort Gambale, Elisabetta
collection PubMed
description Several small molecules, epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib and afatinib, have been demonstrated to significantly improve clinical outcomes in patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC), but erlotinib activity in EGFR wild-type squamous carcinoma is still highly debated. Here, we describe a prolonged and unexpected clinical response to erlotinib in a male former heavy cigarette smoker with wild-type EGFR squamous-cell cancer.
format Online
Article
Text
id pubmed-5449169
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-54491692017-06-02 Extraordinary and prolonged erlotinib-induced clinical response in a patient with EGFR wild-type squamous lung cancer in third-line therapy: a case report Gambale, Elisabetta Carella, Consiglia Amerio, Paolo Buttitta, Fiamma Patea, Rosa Lucia Natoli, Clara De Tursi, Michele Int Med Case Rep J Case Report Several small molecules, epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib and afatinib, have been demonstrated to significantly improve clinical outcomes in patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC), but erlotinib activity in EGFR wild-type squamous carcinoma is still highly debated. Here, we describe a prolonged and unexpected clinical response to erlotinib in a male former heavy cigarette smoker with wild-type EGFR squamous-cell cancer. Dove Medical Press 2017-05-23 /pmc/articles/PMC5449169/ /pubmed/28579838 http://dx.doi.org/10.2147/IMCRJ.S134944 Text en © 2017 Gambale et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Case Report
Gambale, Elisabetta
Carella, Consiglia
Amerio, Paolo
Buttitta, Fiamma
Patea, Rosa Lucia
Natoli, Clara
De Tursi, Michele
Extraordinary and prolonged erlotinib-induced clinical response in a patient with EGFR wild-type squamous lung cancer in third-line therapy: a case report
title Extraordinary and prolonged erlotinib-induced clinical response in a patient with EGFR wild-type squamous lung cancer in third-line therapy: a case report
title_full Extraordinary and prolonged erlotinib-induced clinical response in a patient with EGFR wild-type squamous lung cancer in third-line therapy: a case report
title_fullStr Extraordinary and prolonged erlotinib-induced clinical response in a patient with EGFR wild-type squamous lung cancer in third-line therapy: a case report
title_full_unstemmed Extraordinary and prolonged erlotinib-induced clinical response in a patient with EGFR wild-type squamous lung cancer in third-line therapy: a case report
title_short Extraordinary and prolonged erlotinib-induced clinical response in a patient with EGFR wild-type squamous lung cancer in third-line therapy: a case report
title_sort extraordinary and prolonged erlotinib-induced clinical response in a patient with egfr wild-type squamous lung cancer in third-line therapy: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5449169/
https://www.ncbi.nlm.nih.gov/pubmed/28579838
http://dx.doi.org/10.2147/IMCRJ.S134944
work_keys_str_mv AT gambaleelisabetta extraordinaryandprolongederlotinibinducedclinicalresponseinapatientwithegfrwildtypesquamouslungcancerinthirdlinetherapyacasereport
AT carellaconsiglia extraordinaryandprolongederlotinibinducedclinicalresponseinapatientwithegfrwildtypesquamouslungcancerinthirdlinetherapyacasereport
AT ameriopaolo extraordinaryandprolongederlotinibinducedclinicalresponseinapatientwithegfrwildtypesquamouslungcancerinthirdlinetherapyacasereport
AT buttittafiamma extraordinaryandprolongederlotinibinducedclinicalresponseinapatientwithegfrwildtypesquamouslungcancerinthirdlinetherapyacasereport
AT patearosalucia extraordinaryandprolongederlotinibinducedclinicalresponseinapatientwithegfrwildtypesquamouslungcancerinthirdlinetherapyacasereport
AT natoliclara extraordinaryandprolongederlotinibinducedclinicalresponseinapatientwithegfrwildtypesquamouslungcancerinthirdlinetherapyacasereport
AT detursimichele extraordinaryandprolongederlotinibinducedclinicalresponseinapatientwithegfrwildtypesquamouslungcancerinthirdlinetherapyacasereport

Ejemplares similares